Startseite Kongressberichte & Archiv 59th ASH Annual Meeting and Exposition Press Conferences Enhancing Care in Hematologic Malignancies through Targeted Therapies

Enhancing Care in Hematologic Malignancies through Targeted Therapies

Webcasts at the bottom (by courtesy of VJHemOnc)

Abstracts: 

817  Youn H. Kim, Martine Bagot, Lauren Pinter-Brown, et al. Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study.

The authors of this study conclude that:

In this first report of a randomized Phase III study evaluating PFS as primary endpoint in CTCL, Moga, a novel CCR4-targeting antibody therapy, demonstrated significantly superior PFS, ORR, and QoL compared to Vor in patients with previously treated CTCL. The safety profile was consistent with previous reports. This study supports Moga as a valuable new therapeutic option in patients with CTCL.

 

2 Daniel J. DeAngelo, Albert Thomas Quiery, Deepti Radia, Mark W Drummond, et al. Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V  in Advanced Systemic Mastocytosis (AdvSM)

The authors of this study conclude that:

 BLU-285, a potent, highly-selective inhibitor of KIT D816V and other activation loop mutants is well tolerated at the 300 mg RP2D and demonstrates considerable clinical activity in all AdvSM subtypes, including pts who have failed midostaurin and other anti-neoplastic therapies. These encouraging phase 1 data validate selective targeting of KIT D816V and warrant further clinical testing of BLU-285 in SM.

 

428 Peter Hillmen, Talha Munir, Andy Rawstron,  Kristian Brock, et al. Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

The authors of this study conclude that:

The combination of IBR with VEN is well tolerated in relapsed, refractory CLL with only two of 41 patients experiencing biochemical TLS to date. All 25 patients reaching the initial response assessment after 6 months of IBR+VEN have responded, 60% are in CR & 28% have achieved an MRD negative remission in the marrow. These early results suggest a potent synergy between ibrutinib & venetoclax.

 

6 Joseph M Connors, Wojciech Jurczak, PhD, David J. Straus, Stephen M. Ansell et al. Brentuximab Vedotin Plus Doxorubicin, Vinblastine, Dacarbazine (A+AVD) As Frontline Therapy Demonstrates Superior Modified Progression-Free Survival Versus ABVD in Patients with Previously Untreated Stage III or IV Hodgkin Lymphoma (HL): The Phase 3 Echelon-1 Study

The authors of this study conclude that:

Compared with standard ABVD, A+AVD as frontline therapy improves outcome for patients with advanced HL including a 23% risk reduction in progression, death, or need for additional anticancer therapy. This establishes A+AVD as a new frontline option for patients with advanced-stage HL.

 

See also the article which appeared simultaneously in the NEJM:

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma Joseph M. Connors, M.D., Wojciech Jurczak, M.D., Ph.D., David J. Straus, M.D., Stephen M. Ansell, M.D., Ph.D., et al. for the ECHELON-1 Study Group